Table 1.
Demographics and clinical characteristics of subjects included in study 1, 2 and 3
| Control | sAD | fAD | PA | |
|---|---|---|---|---|
| Study 1 | n = 4 | n = 4 | ||
| Brain region | Parietal cortex | Parietal cortex | ||
| Gender (male/female) | 1/3 | 1/3 | ||
| Age at death (years) | 64.25 [3.40] | 64.50 [2.52] | ||
| Post-mortem delay, (h) | 6.66 [1.19] | 5.72 [0.59] | ||
| Braak stage 0-I/II-IV/V-VI | 4/0/0 | 0/0/4 | ||
| Nlgn1 band signal (F-7 ab) | 4425 [419.5] | 2374 [914.5] |
| Control | sAD | fAD | PA | |
|---|---|---|---|---|
| Study 2 | n = 7 | n = 9 | n = 9 | n = 15 |
| Brain region | Temporal cortex | Temporal cortex | Temporal cortex | Temporal cortex |
| Gender (male/female) | 4/3 | 6/3 | 3/6 | 4/11 |
| Age at death (years) | 74.14 [18.42] | 72.11 [8.3] | 52.67 [9.99] | 86.33 [5.96] |
| Post-mortem delay (h) | 58.96 [22.77] | 71.17 [19.05] | 38.8 [17.74] | 76.25 [31.08] |
| Braak stages 0/I-II/III-IV/V-VI | 5/2/0/0 | 0/0/0/9 | 0/0/0/9 | 0/4/11/0 |
| Thal phases 0/1–2/3/4–5 | 5/2/0/0 | 0/0/0/9 | 0/0/0/9 | 0/4/5/6 |
| CERAD score (0/1/2/3) | 6/1/0/0 | 0/0/1/8 | 0/0/0/9 | 2/8/5/0 |
| CAA (0/1/2/3) | 5/1/1/0 | 0/4/3/2 | 0/1/1/7 | 6/2/6/1 |
| Nlgn1 WB quantification (samples ng/QC ng; 20 µg brain homogenate) | 2.22 [0.96] | 0.85 [0.57] | 0.97 [0.58] | 1.78 [0.80] |
| Control | sAD | PSP | CBD | PiD | |
|---|---|---|---|---|---|
| Study 3 | n = 10 | n = 10 | n = 11 | n = 10 | n = 9 |
| Brain region | Frontal grey matter | Frontal grey matter | Frontal grey matter | Frontal grey matter | Frontal grey matter |
| Gender (male/female) | 4/6 | 6/4 | 6/5 | 7/3 | 8/1 |
| Age at death (years) | 78.7 [17.65] | 69.4 [8.13] | 79.27 [9.04] | 68.6 [4.93] | 69.78 [4.79] |
| Post-mortem delay, (h) | 77.45 [42.8] | 56.05 [26.32] | 47.93 [21.63] | 72.86 [25.05] | 67.39 [27.28] |
| Braak stages 0/I-II/III-IV/V-VI | 3/7/0/0 | 0/0/0/10 | na | na | na |
| Thal phases 0/1–2/3/4–5 | 4/4/1/1 | 0/0/0/10 | na | na | na |
| CAA (0/1/2/3) | 8/2/0/0 | 1/1/1/7 | na | na | na |
|
Nlgn1 WB quantification (samples ng/QC ng; 20 µg brain homogenate) |
0.92 [0.29] | 0.56 [0.35] | 0.65 [0.33] | 0.45 [0.21] | 0.42 [0.27] |
The data are presented as mean and [standard deviation]
WB Western blot, Na not available, CAA cerebral amyloid angiopathy, 0 = none, 1 = mild, 2 = moderate, 3 = severe